Guangqin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guangqin Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jinping Wang
Department of Neurology, Chongqing University Central Hospital, Chongqing 400050, China
3 shared publications - Mingsu Liu
Department of Neurology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
3 shared publications - Xun Yang
Department of Neurology, Hechuan District People's Hospital, Chongqing 401500, China
3 shared publications - Chenxi Liu
Department of Neurology, The Frist Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2 shared publications Chenxi Liu
Department of Neurology, The Frist Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
1 shared publicationChenxi Mm Liu
Department of Neurology, The Frist Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- 3 March 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 239, 108229
The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting
- 3 March 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 239, 108229
The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting
- Open Access
- 6 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (40) , e35091
Systematic review and meta-analysis of the efficacy and safety of adjunctive use of tirofiban in patients treated with endovascular therapy for acute ischemic stroke at different embolic sites
Background: The use of tirofiban as an adjunct to endovascular therapy (EVT) for acute ischemic stroke has been controversial. We aimed to assess the differences in safety and efficacy of EVT adjuvant to tirofiban in patients with anterior circulation stroke (ACS) and posterior circulation stroke (PCS). Methods: We systematically searched Pubmed, Embase, Cochrane Library, and Web of Science. Cohort studies and randomized controlled trials that compared treatment with tirofiban combined with EVT and EVT alone were included in our meta-analysis. The safety outcomes were symptomatic intracranial hemorrhage, and 3-month mortality. The efficacy outcomes were good functional outcome, excellent functional outcome, and successful recanalization (mTICI ≥ 2b). We performed subgroup analyses of anterior and posterior circulation strokes. Results: We included 15 studies with 4608 patients. For safety outcomes, tirofiban significantly reduced 3-month mortality in the ACS subgroup (odd ratio [OR] = 0.80, 95% confidence interval [CI] = 0.65–0.98, P = .03) without increasing the rate of symptomatic intracranial hemorrhage (OR = 1.12, 95% CI = 0.88–1.44, P = .35). In the PCS subgroup, tirofiban significantly reduced 3-month mortality (OR = 0.63, 95% CI = 0.50–0.80, P = .0001) and symptomatic intracranial hemorrhage (OR = 0.60, 95% CI = 0.37–0.95, P = .03). For efficacy outcomes, in the ACS subgroup, tirofiban significantly improved good functional outcome (OR = 1.24, 95% CI = 1.06–1.45, P = .008) but did not improve recanalization (OR = 1.17, 95% CI = 0.93–1.47, P = .17) and excellent functional outcome (OR = 1.19, 95% CI = 0.97–1.46, P = .10). In the PCS subgroup, tirofiban significantly improved recanalization rate (OR = 1.94, 95% CI = 1.43–2.65, P < .0001) and did not improve good functional outcome (OR = 1.03, 95% CI = 0.81–1.30, P = .81) and excellent functional outcome (OR = 0.84, 95% CI = 0.58–1.20, P = .34). Conclusion: In acute ischemic stroke patients undergoing EVT, tirofiban improves good functional outcomes in ACS patients and increases recanalization rates in PCS patients on the 1 hand, reduces mortality, and does not increase the risk of symptomatic intracranial hemorrhage on the other. Tirofiban is safe and effective in both anterior circulation stroke and posterior circulation stroke patients undergoing EVT. More large multicentre randomized controlled studies are needed in the future.
- 6 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (40) , e35091
Open AccessSystematic review and meta-analysis of the efficacy and safety of adjunctive use of tirofiban in patients treated with endovascular therapy for acute ischemic stroke at different embolic sites
Background: The use of tirofiban as an adjunct to endovascular therapy (EVT) for acute ischemic stroke has been controversial. We aimed to assess the differences in safety and efficacy of EVT adjuvant to tirofiban in patients with anterior circulation stroke (ACS) and posterior circulation stroke (PCS). Methods: We systematically searched Pubmed, Embase, Cochrane Library, and Web of Science. Cohort studies and randomized controlled trials that compared treatment with tirofiban combined with EVT and EVT alone were included in our meta-analysis. The safety outcomes were symptomatic intracranial hemorrhage, and 3-month mortality. The efficacy outcomes were good functional outcome, excellent functional outcome, and successful recanalization (mTICI ≥ 2b). We performed subgroup analyses of anterior and posterior circulation strokes. Results: We included 15 studies with 4608 patients. For safety outcomes, tirofiban significantly reduced 3-month mortality in the ACS subgroup (odd ratio [OR] = 0.80, 95% confidence interval [CI] = 0.65–0.98, P = .03) without increasing the rate of symptomatic intracranial hemorrhage (OR = 1.12, 95% CI = 0.88–1.44, P = .35). In the PCS subgroup, tirofiban significantly reduced 3-month mortality (OR = 0.63, 95% CI = 0.50–0.80, P = .0001) and symptomatic intracranial hemorrhage (OR = 0.60, 95% CI = 0.37–0.95, P = .03). For efficacy outcomes, in the ACS subgroup, tirofiban significantly improved good functional outcome (OR = 1.24, 95% CI = 1.06–1.45, P = .008) but did not improve recanalization (OR = 1.17, 95% CI = 0.93–1.47, P = .17) and excellent functional outcome (OR = 1.19, 95% CI = 0.97–1.46, P = .10). In the PCS subgroup, tirofiban significantly improved recanalization rate (OR = 1.94, 95% CI = 1.43–2.65, P < .0001) and did not improve good functional outcome (OR = 1.03, 95% CI = 0.81–1.30, P = .81) and excellent functional outcome (OR = 0.84, 95% CI = 0.58–1.20, P = .34). Conclusion: In acute ischemic stroke patients undergoing EVT, tirofiban improves good functional outcomes in ACS patients and increases recanalization rates in PCS patients on the 1 hand, reduces mortality, and does not increase the risk of symptomatic intracranial hemorrhage on the other. Tirofiban is safe and effective in both anterior circulation stroke and posterior circulation stroke patients undergoing EVT. More large multicentre randomized controlled studies are needed in the future.
- 30 September 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 234, 108005
Efficacy and safety of bridging therapy versus direct thrombectomy for tandem lesions in acute stroke: A systematic review and meta-analysis
- 30 September 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 234, 108005
Efficacy and safety of bridging therapy versus direct thrombectomy for tandem lesions in acute stroke: A systematic review and meta-analysis
- 28 March 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 228, 107702
Meta-analysis of the efficacy and safety of tirofiban in patients with acute ischaemic stroke undergoing mechanical thrombectomy
- 28 March 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 228, 107702
Meta-analysis of the efficacy and safety of tirofiban in patients with acute ischaemic stroke undergoing mechanical thrombectomy
- 1 August 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (8) , 105755
Thrombotic Pathology is not Correlated with the Prognosis of Endovascular Treatment for Acute Ischemic Stroke
- 1 August 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (8) , 105755
Thrombotic Pathology is not Correlated with the Prognosis of Endovascular Treatment for Acute Ischemic Stroke